BioCentury | Oct 26, 2018
Company News

NeoGenomics to acquire Genoptix

...NYSE:NVS; SIX:NOVN). Ampersand Capital Partners and 1315 Capital acquired the company from Novartis in 2017. Genoptix Inc....
...Business: Diagnostic NeoGenomics Inc. (NASDAQ:NEO) said it will acquire hematology and solid tumor testing company Genoptix Inc....
...In August, NeoGenomics raised $125 million in a follow-on (see "Neogenomics Raises $125M Follow-on" ). Shannon Lehnbeuter Genoptix Inc. NeoGenomics...
BioCentury | Jul 21, 2014
Company News

Illumina management update

...Nova as SVP and general manager of Illumina’s oncology business, formerly president and CEO of Genoptix...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

...sum. Jimenez also made a couple of small diagnostics acquisitions, including personalized diagnostic services company Genoptix Inc....
BioCentury | Dec 24, 2012
Finance

Highlights of weekly biotech stock moves

...of Procysbi sales. Trovagene Inc. (NASDAQ:TROV) gained $1.01 (16%) to $7.28 last week after granting Genoptix Inc....
...nucleophosmin ( NPM1 ; B23) in research and clinical testing for acute myelogenous leukemia (AML). Genoptix...
BioCentury | Dec 24, 2012
Company News

Trovagene, Novartis deal

...Trovagene granted Novartis' Genoptix Inc. a worldwide, non-exclusive license to use nucelophosmin ( NPM1 ; B23) in...
...will receive an upfront payment and is eligible for royalties. Financial terms were not disclosed. Genoptix...
BioCentury | Jul 25, 2011
Company News

Genoptix, Novartis deal

...company Genoptix for $25 per share in cash, or $458 million (see BioCentury, March 7). Genoptix Inc....
BioCentury | Mar 7, 2011
Company News

Genoptix, Novartis deal

...SIX:NOVN), Basel, Switzerland Business: Diagnostic Novartis began a subsequent tender offer to acquire diagnostic company Genoptix...
BioCentury | Jan 31, 2011
Finance

Highlights of weekly biotech stock moves

...other on sales in their respective territories. Orion lost €0.05 to €16.61 on the week. Genoptix Inc....
...acquire the diagnostic service company for $25 per share in cash, or about $470 million. Genoptix...
BioCentury | Jan 31, 2011
Company News

Genoptix, Novartis deal

...Novartis will acquire Genoptix for $25 per share in cash, or about $470 million. The price...
...27% premium to Genoptix's close of $19.76 on Jan. 21, before the deal was announced. Genoptix...
...unanimously approved by Genoptix's Board, is expected to close this half. Barclays Capital advised Genoptix. Genoptix Inc....
BioCentury | Jan 25, 2011
Company News

Novartis to acquire Genoptix

...Novartis AG (NYSE:NVS; SIX:NOVN) will acquire diagnostic service company Genoptix Inc. (NASDAQ:GXDX) for $25 per share in...
...is a 27% premium to Genoptix's Friday close of $19.76, before the deal was announced. Genoptix...
...unanimously approved the deal, which is expected to close this half. Barclays Capital advised Genoptix. Genoptix...
Items per page:
1 - 10 of 36
BioCentury | Oct 26, 2018
Company News

NeoGenomics to acquire Genoptix

...NYSE:NVS; SIX:NOVN). Ampersand Capital Partners and 1315 Capital acquired the company from Novartis in 2017. Genoptix Inc....
...Business: Diagnostic NeoGenomics Inc. (NASDAQ:NEO) said it will acquire hematology and solid tumor testing company Genoptix Inc....
...In August, NeoGenomics raised $125 million in a follow-on (see "Neogenomics Raises $125M Follow-on" ). Shannon Lehnbeuter Genoptix Inc. NeoGenomics...
BioCentury | Jul 21, 2014
Company News

Illumina management update

...Nova as SVP and general manager of Illumina’s oncology business, formerly president and CEO of Genoptix...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

...sum. Jimenez also made a couple of small diagnostics acquisitions, including personalized diagnostic services company Genoptix Inc....
BioCentury | Dec 24, 2012
Finance

Highlights of weekly biotech stock moves

...of Procysbi sales. Trovagene Inc. (NASDAQ:TROV) gained $1.01 (16%) to $7.28 last week after granting Genoptix Inc....
...nucleophosmin ( NPM1 ; B23) in research and clinical testing for acute myelogenous leukemia (AML). Genoptix...
BioCentury | Dec 24, 2012
Company News

Trovagene, Novartis deal

...Trovagene granted Novartis' Genoptix Inc. a worldwide, non-exclusive license to use nucelophosmin ( NPM1 ; B23) in...
...will receive an upfront payment and is eligible for royalties. Financial terms were not disclosed. Genoptix...
BioCentury | Jul 25, 2011
Company News

Genoptix, Novartis deal

...company Genoptix for $25 per share in cash, or $458 million (see BioCentury, March 7). Genoptix Inc....
BioCentury | Mar 7, 2011
Company News

Genoptix, Novartis deal

...SIX:NOVN), Basel, Switzerland Business: Diagnostic Novartis began a subsequent tender offer to acquire diagnostic company Genoptix...
BioCentury | Jan 31, 2011
Finance

Highlights of weekly biotech stock moves

...other on sales in their respective territories. Orion lost €0.05 to €16.61 on the week. Genoptix Inc....
...acquire the diagnostic service company for $25 per share in cash, or about $470 million. Genoptix...
BioCentury | Jan 31, 2011
Company News

Genoptix, Novartis deal

...Novartis will acquire Genoptix for $25 per share in cash, or about $470 million. The price...
...27% premium to Genoptix's close of $19.76 on Jan. 21, before the deal was announced. Genoptix...
...unanimously approved by Genoptix's Board, is expected to close this half. Barclays Capital advised Genoptix. Genoptix Inc....
BioCentury | Jan 25, 2011
Company News

Novartis to acquire Genoptix

...Novartis AG (NYSE:NVS; SIX:NOVN) will acquire diagnostic service company Genoptix Inc. (NASDAQ:GXDX) for $25 per share in...
...is a 27% premium to Genoptix's Friday close of $19.76, before the deal was announced. Genoptix...
...unanimously approved the deal, which is expected to close this half. Barclays Capital advised Genoptix. Genoptix...
Items per page:
1 - 10 of 36